Vera Therapeutics Reports Q3 2026 Revenue of $10.3 Million, Net Loss Per Share of $1. ...
Commercial Launch of TRUTAKNA Drives Revenue Beat as Company Files for Full FDA Approval Related Stocks: VERA ,
Commercial Launch of TRUTAKNA Drives Revenue Beat as Company Files for Full FDA Approval Related Stocks: VERA ,